THDB(SH:600867)2014-10-22 16:00Financial Performance - Operating revenue for the first nine months reached CNY 1,028,970,377.25, a 19.00% increase year-on-year [8]. - Net profit attributable to shareholders of the listed company rose by 16.47% to CNY 219,328,706.08 for the same period [8]. - Basic earnings per share increased by 5.00% to CNY 0.21 [9]. - Total operating revenue for Q3 2014 reached ¥373,289,310.07, an increase of 19.3% compared to ¥313,005,854.58 in Q3 2013 [41]. - The net profit attributable to shareholders for Q3 2014 was CNY 70,212,972.63, slightly down from CNY 71,051,038.10 in Q3 2013, representing a decrease of 1.2% [45]. - The total comprehensive income attributable to the parent company for Q3 2014 was CNY 77,735,472.63, compared to CNY 72,453,538.10 in the same period last year, reflecting an increase of 7.4% [45]. - The operating profit for the first nine months of 2014 was CNY 255,793,954.15, up from CNY 231,162,064.33 in the same period last year, indicating a growth of 10.7% [45]. Cash Flow - The net cash flow from operating activities decreased by 37.94% to CNY 128,858,650.81 compared to the previous year [8]. - The net cash flow from operating activities for the first nine months of 2014 was CNY 128,858,650.81, down from CNY 207,639,708.99 in the same period last year, a decrease of 38.0% [48]. - The net cash flow from investing activities improved, with a decrease in outflow to ¥-59,090,954.96 from ¥-185,409,383.72 year-on-year [19]. - The net cash flow from financing activities showed a significant change, decreasing to ¥-27,917,267.43 from a positive inflow of ¥5,231,603.46 in the previous year [19]. - The total cash outflow for operating activities was CNY 765,410,914.83, an increase from CNY 680,139,283.27 year-over-year, reflecting higher operational costs [51]. - The net increase in cash and cash equivalents for the period was -CNY 121,788,151.02, contrasting with an increase of CNY 27,927,455.06 in the previous year, indicating a challenging cash flow situation [52]. Assets and Liabilities - Total assets increased by 9.09% to CNY 2,939,374,692.23 compared to the end of the previous year [8]. - Total assets as of September 30, 2014, amounted to ¥2,945,153,043.98, compared to ¥2,712,353,637.23 at the beginning of the year [37]. - Total liabilities increased to ¥755,556,407.33 from ¥607,653,799.00 at the beginning of the year, reflecting a growth of 24.3% [37]. - Shareholders' equity totaled ¥2,189,596,636.65, up from ¥2,104,699,838.23 at the start of the year, indicating a growth of 4.0% [37]. - The company's short-term borrowings rose to ¥380,000,000.00 from ¥253,000,000.00 at the beginning of the year [32]. - Long-term borrowings increased to ¥302,000,000.00 from ¥256,350,685.00, reflecting an increase of 17.8% [37]. Expenses - Sales expenses increased by 33.16% to CNY 330,516,158.68 compared to the same period last year [17]. - Financial expenses increased by 37.16% to CNY 16,157,677.16 year-on-year [17]. - The increase in sales expenses was primarily due to higher investments in market development for the restructured human insulin products [21]. - The increase in financial expenses was attributed to an increase in borrowings during the period [21]. Stock and Incentives - The company plans to implement a stock option and restricted stock incentive plan, granting 8,324,000 stock options and 5,500,000 restricted shares [23].